ClinicalTrials.gg
Status unknownNCT04980651Updated Oct 2, 2024

Safety and Efficacy of Remote Ischemic Conditioning for Acute Ischemic Stroke

An interventional study of Remote ischemic conditioning and Sham remote ischemic conditioning in Acute Ischemic Stroke, sponsored by Yi Yang. Status unknown at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-02.

Sponsored by Yi Yang · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Feb 2024), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
2,210
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to determine the efficacy and safety of remote ischemic conditioning for acute ischemic stroke.

Read the detailed description

In this study, 2210 cases of ischemic stroke in 72 hours were included in 10 centers in China according to the principle of random, and parallel control. The experimental group receive basic treatment and remote ischemic conditioning for 200mmHg, 2 times per day for 7 consecutive days. The control group receive basic treatment and remote ischemic conditioning control for 60mmHg, 2 times per day for 7 consecutive days. Two groups will be followed up for 90 days to evaluate the efficacy and safety of remote ischemic conditioning in treating acute ischemic stroke.

02

Conditions studied

  • Acute Ischemic Stroke

Browse trials for

03

In context

Ischemic Stroke

2,653 studies on the registry are indexed under Ischemic Stroke; 936 are open to participants now.

This study's planned enrollment of 2,210 is above the median of 120 across 1,799 interventional studies indexed under Ischemic Stroke.

Browse Ischemic Stroke studies →

Lead sponsor

Yi Yang is the lead sponsor of 43 studies on the registry; 25 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1) Age≥18 years, regardless of sex.
  • 2) Patients with clinically definite diagnosis of acute ischemic stroke and able to commence RIC treatment within 72 hours of stroke onset.
  • 3) Baseline NIHSS ≥ 4, ≤ 24.
  • 4) Baseline mRS ≤ 2;
  • 5) Signed and dated informed consent is obtained.

Exclusion criteria

Exclusion Criteria:

  • 1) Patients who undergo thrombolytic therapy or endovascular treatment.
  • 2) The patients who had the contraindication of remote ischemic conditioning treatment, such as severe soft tissue injury, fracture, or vascular injury in the upper limb. Acute or subacute venous thrombosis, arterial occlusive disease, subclavian steal syndrome, etc.
  • 3) Other intracranial lesions, such as cerebrovascular malformation cerebral venous diseases, tumors,s and other diseases involving the brain.
  • 4) Pregnant or lactating women.
  • 5) Previous remote ischemic conditioning therapy or similar treatment.
  • 6) Severe hepatic and renal dysfunction.
  • 7) Patients with a life expectancy of less than 3 months or patients unable to complete the study for other reasons.
  • 8) Unwilling to be followed up or treated for poor compliance.
  • 9) He/She is participating in other clinical research or has participated in other clinical research or has participated in this study within 3 months prior to admission.
  • 10) Other conditions that the researchers think are not suitable for the group.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
2,210 participants (estimated)

Study arms

  • Active comparator
    RIC+Standard medical treatment

    Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 200 mm Hg. RIC will be conducted twice daily for 7 consecutive days. Additionally, the patients will be treated with standard medical treatment according to the Guidelines for diagnosis and treatment of acute ischemic stroke in China 2014.

    Procedure: Remote ischemic conditioning

  • Placebo comparator
    Sham RIC+Standard medical treatment

    Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 60 mm Hg. RIC will be conducted twice daily for 7 consecutive days. Additionally, the patients will be treated with standard medical treatment according to the Guidelines for diagnosis and treatment of acute ischemic stroke in China 2014.

    Procedure: Sham remote ischemic conditioning

Interventions

  • ProcedureRemote ischemic conditioning

    Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 200 mm Hg.

  • ProcedureSham remote ischemic conditioning

    Sham remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 60 mm Hg.

06

What researchers measure

Primary outcomes

  1. Proportion of patients with modified Rankin Scale (mRS) Score 0-2.

    Proportion of patients with modified Rankin Scale (mRS) Score 0-2. Ranged from 0 to 6, a low value represents a better outcome.

    Time frame: 3 months

Secondary outcomes

  1. National Institute of Health stroke scale (NIHSS) at 7 days, 30±3 days, 90±3 days from onset.

    National Institute of Health stroke scale (NIHSS) at 24 hours, 7 days, 30±3 days, 90±3 days from onset. Ranged from 0 to 42, a low value represents a better outcome.

    Time frame: 7days, 30±3 days, 90±3 days

  2. modified Rankin Scale (mRS) Score at 7 days, 30±3 days, 90±3 days from onset.

    modified Rankin Scale (mRS) at 24 hours, 7 days, 30±3 days, 90±3 days from onset. Ranged from 0 to 6, a low value represents a better outcome.

    Time frame: 7days, 30±3 days, 90±3 days

  3. Barthel Index (BI) at 7 days, 30±3 days, 90±3 days from onset.

    Barthel Index (BI) at 7 days, 30±3 days, 90±3 days from onset. Ranged from 0 to 100, a high value represents a better outcome.

    Time frame: 7days, 30±3 days, 90±3 days

  4. Proportion of patients with hemorrhagic transformation during hospitalization.

    Proportion of patients with hemorrhagic transformation during hospitalization.

    Time frame: 7 days

  5. Frequency of adverse events during follow-up.

    Severe adverse events through day-90 after the onset of acute ischemic stroke.

    Time frame: 90 days

Other outcomes

  1. Blood pressure at 24 hours, 7 days, 30±3 days, 90±3 days.

    Blood pressure at 24 hours, 7 days, 30±3 days, 90±3 days.

    Time frame: 24 hours, 7 days, 30±3 days, 90±3 days

  2. heart rate at 24 hours, 7 days, 30±3 days, 90±3 days.

    heart rate at 24 hours, 7 days, 30±3 days, 90±3 days.

    Time frame: 24 hours, 7 days, 30±3 days, 90±3 days

  3. Numeric rating scales (NRS) score during intervention.

    Numeric rating scales (NRS) score during intervention. Ranged from 0 to 10, a low value represents a less pain.

    Time frame: 7 days

  4. Proportion of patients with early withdrawal for safety or tolerability reasons.

    Proportion of patients with early withdrawal for safety or tolerability reasons.

    Time frame: 7 days

07

Study locations

1 of 1 sites recruiting
  • The First Hospital of Jilin University
    Changchun, Jilin 130000, China
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 2, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04980651
Lead sponsor
Yi Yang
Responsible party
Yi Yang (Associated Dean of First Hospital of Jilin University, The First Hospital of Jilin University) — Sponsor-investigator
First posted
Jul 28, 2021
Start date
Jul 1, 2021
Primary completion
Jul 1, 2025 (estimated)
Completion
Oct 1, 2025 (estimated)
Last update
Oct 2, 2024

Study contacts

Yi Yang, MD, PhD
Contact
doctor_yangyi@163.com
0086-13756661217
Zhenni Guo, MD, PhD
Contact
zhen1ni2@163.com

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion